LGBCL: phase 2 study of intensified rituximab induction and maintenance

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • In patients with newly diagnosed or rituximab-naive low-grade B-cell lymphoma (LGBCL), intensified rituximab (Rituxan) induction and maintenance delivered tolerable, impressive efficacy

Why this matters

  • Risk scoring systems such as Sokal and European Treatment and Outcome Study (EUTOS) currently incorporate peripheral blood (PB) parameters.

Study design

  • Phase 2 study to investigate the safety and efficacy of rituximab (Rituxan) as 8 weekly doses of induction and 2 y maintenance therapy in 36 patients with newly diagnosed or rituximab-naive LGBCL.
  • Funding: Grant-in-Aid for Cli...